TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01102426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Description: plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
Study: NCT03248076

Intervention type: DRUG
Intervention: Fentanyl Citrate
Description: 1γ/Kg fentanyl
Study: NCT01706055

Intervention type: BIOLOGICAL
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
Study: NCT03845647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral central lymph node dissection
Description: contralateral central lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral central lymph node dissection
Description: contralateral central lymph node dissection
Study: NCT01295957

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reminiscence therapy
Description: 24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: comparison group
Description: The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: control
Description: advise and informal counseling
Study: NCT04359160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthense, Orthense, Digikare Inc. Blagnac, France
Description: Mobile-app follow-up care, with questions and score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Paper questionnaire follow-up, with questions and score
Study: NCT00871494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
Study: NCT02755909

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-anesthetic Education
Description: Education was done before the anesthetic procedure, using a flip chart made by the researchers.
Study: NCT03636295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
Study: NCT02271841

Intervention type: DEVICE
Intervention: PVI
Description: Pleth Variability Index
Study: NCT04769219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary prevention training
Description: Secondary prevention training will be given after acute myocardial infarction
Study: NCT01970683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL #3 BID

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: VSL #3 BID
Study: NCT00062478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin (BNP1350)
Description: Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
Study: NCT02975609

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated Radiotherapy
Description: 5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
Study: NCT00830466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laser and rapamycin versus laser alone
Description: Laser and rapamycin versus laser alone
Study: NCT02975609

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 30Gy/3-5F for the primary and the metastases.
Study: NCT02152761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
Study: NCT04098458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NDURE
Description: NDURE consists of 6 key functions including (1) Improve patient knowledge about guidelines for timely PORT and associated care processes; (2) Minimize the burden of travel for HNSCC care; (3) Improve communication between patients and providers regarding intentions and goals for timely, guideline-adherent PORT; (4) Enhance coordination of care between healthcare teams during care transitions and about treatment sequelae; (5) Track referrals to ensure timely scheduling of appointments and patient attendance across fragmented healthcare systems; (6) Restructure the organization to clarify roles and responsibilities for care processes associated with PORT delivery to avoid duplication and gaps in care. Direct contact between the NDURE navigator and patient occurs via three clinic-based, face-to-face NDURE sessions lasting 30-60 minutes each at the pre-surgical consult, hospital discharge, and first postoperative visit.
Study: NCT03189628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stromal vascular fraction
Description: The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
Study: NCT03143283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Study Lethal Means Counseling
Description: Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
Study: NCT04855968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In addition to standard post-op medication patient will have access to the head space meditation application.
Description: Patients will receive access to head space meditation application in addition to standard pain medication post surgery.
Study: NCT02845752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stiolto Respimat
Description: Oral inhalation spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stiolto Respimat
Description: Oral inhalation spray
Study: NCT04855968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients will take standard post-op pain medication
Description: Standard post-op pain medication
Study: NCT03203967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Description: 2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Epidural placebo
Description: 5 ml normal saline is administered through the epidural catheter at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single femoral nerve block
Description: Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single femoral nerve block
Description: Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous morphine analgesia
Description: Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous morphine analgesia
Description: Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
Study: NCT00494702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuscitation
Description: Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation
Description: Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
Study: NCT03732963

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Group P)
Description: Group P: 20 patients will receive a placebo tablet preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin (Group M)
Description: Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
Study: NCT04362670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-CSI
Description: OTX-CSI intracanalicular insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-CSI
Description: OTX-CSI intracanalicular insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-CSI
Description: OTX-CSI intracanalicular insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Hydrogel Vehicle intracanalicular insert

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Hydrogel Vehicle intracanalicular insert
Study: NCT05016739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADISS
Description: The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure.
Study: NCT01330303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test formulation
Description: tamsulosin hydrochloride 0,4 mg (Synthon BV)
Study: NCT03564158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem-vaborbactam
Description: Meropenem-Vaborbactam being studied for effects on TQT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem-vaborbactam
Description: Meropenem-Vaborbactam being studied for effects on TQT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03799965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS (Enhanced Recovery After Surgery ) are evaluated
Description: In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS are not evaluated
Description: In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
Study: NCT02152761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimagrumab
Description: Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
Study: NCT01255618

Intervention type: DEVICE
Intervention: INVOS 5100
Description: Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
Study: NCT02885714

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo surgery and supervised specific exercises
Description: The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair and supervised specific exercises
Description: The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
Study: NCT00002723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: 3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: 5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
Study: NCT03564158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Active Comparator
Study: NCT04629378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Meropenem IV 6 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Meropenem IV 6 grams

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amx/CA oral 1000/62.5mg 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: Amx/CA oral 1000/62.5mg 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide 20-30mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour (HRZE) Standard dose
Study: NCT02535403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT
Study: NCT00149461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plan
Study: NCT02689583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibiotic selection based on the antibiotic susceptibility testing
Description: The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibiotic selection based on the antibiotic susceptibility testing
Description: The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PPI selection based on the CYP2C19 gene polymorphism
Description: PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PPI selection based on the CYP2C19 gene polymorphism
Description: PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
Study: NCT01494077

Intervention type: OTHER
Intervention: Laboratory processing for results
Description: There is no intervention. Extra fluid that is normally discarded will be processed.
Study: NCT00313105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco (Oliver Twist pellets)
Description: individual visits with counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: smoking cessation counseling
Description: individual visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation counseling
Description: individual visits
Study: NCT02845752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat
Description: Oral inhalation spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Respimat
Description: Oral inhalation spray
Study: NCT02852031

Intervention type: OTHER
Intervention: Collaborative Learning Network
Study: NCT04183556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: use of naproxen twice a day orally in mens time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: use of naproxen twice a day orally in mens time

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Turmeric
Description: Use of turmeric orally (1 gram powder formula) in mens time
Study: NCT03266328

Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings

Intervention type: PROCEDURE
Intervention: Primary Percutaneous Coronary Intervention (PPCI)
Description: Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
Study: NCT03934528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual environment activity
Description: Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
Study: NCT02689583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics usage based on the 16SrRNA sequencing
Description: Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
Study: NCT00002723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: 7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.